- Net Income: Zydus Lifesciences reported a net income of 14.2 billion rupees for the first quarter, up 30% year-over-year, exceeding the estimated 12.79 billion rupees.
- Revenue: The company’s revenue reached 62.1 billion rupees, marking a 21% increase year-over-year, and surpassing the expected 58.7 billion rupees.
- Total Costs: Total costs amounted to 43.7 billion rupees, a 14% rise year-over-year, higher than the estimated 39.96 billion rupees.
- Other Income: Zydus Lifesciences reported an other income of 632 million rupees, which is a significant 76% increase year-over-year.
- Share Performance: The company’s shares rose by 3% to 1,318 rupees, with 1.53 million shares traded.
- Analyst Ratings: Zydus Lifesciences has 15 buy ratings, 11 hold ratings, and 6 sell ratings from analysts.
Zydus Lifesciences Ltd on Smartkarma
Analyst coverage on Zydus Lifesciences Ltd by Tina Banerjee on Smartkarma reveals positive sentiment towards the company’s performance. In a recent research report titled “Zydus Lifesciences (ZYDUSLIF IN): Strong India Momentum; Q3 Net Profit Jumps 27%; Buyback Approved,” it was noted that the company achieved strong revenue growth and improved profitability in Q3FY24. Notably, there was a 27% increase in net profit, driven by a 16% YoY and 7% QoQ growth in India formulation business revenue. The profitability improvement was highlighted, with Q3FY24 showing a 200 basis points YoY increase to 24.5%. Furthermore, the approval of a buyback of INR6 billion, representing 0.59% of total outstanding equity shares at a premium price of INR1005 per share, demonstrates confidence in the company’s future outlook.
A look at Zydus Lifesciences Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts at Smartkarma have assessed Zydus Lifesciences Ltd‘s long-term outlook through Smart Scores, with ratings in various areas. With a Growth, Resilience, and Momentum score of 4, the company appears to be positioned well for future expansion and market stability. Additionally, the Value and Dividend scores of 3 signify a balanced financial standing and a potential for investor returns. Zydus Lifesciences Ltd‘s overall outlook seems optimistic based on these scores.
Zydus Lifesciences Ltd is a subsidiary of Cadila Healthcare Ltd., specializing in healthcare solutions such as formulations, active pharmaceutical ingredients, vaccines, and more. Its diverse product range, including tablets, capsules, injections, and ointments, caters to various healthcare needs. With promising Smart Scores across different factors, Zydus Lifesciences Ltd shows potential for sustained growth in the industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
